This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2025
  • /
  • 1
  • /
  • MHRA Approves Seladelpar for PBC
News

MHRA Approves Seladelpar for PBC

Read time: 1 mins
Published:18th Jan 2025
"

The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has  16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called Primary Biliary Cholangitis (PBC), including pruritus.

It works by controlling liver problems in the body and making the liver less inflamed .

Seladelpar belongs to a group of medicines called peroxisome proliferator-activated receptor delta agonists. The medicine can only be prescribed to adult patients with PBC, including pruritus, in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA

Condition: Primary Biliary Cholangitis
Type: drug
How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.